| Patient | Evel Knievel |
|---|---|
| Date of birth | 1968-10-17 |
| Identifiers | MRN HR-RB001-SYN; SSN (made up) 000-01-4927 |
| Document date | 2026-09-21 |
| Author | Dale Rasmussen, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Mr. Knievel is a 57-year-old retired stunt performer with compensated cirrhosis from hepatitis C, cured by 12 weeks of sofosbuvir-velpatasvir, who comes for his yearly preventive visit five weeks after the test that confirmed cure. He has had no alcohol since the start of treatment. He takes carvedilol 12.5 mg daily without dizziness, and had his zoledronic acid infusion in June without a reaction. His pain is about 4 of 10; he goes to the pool twice a week and walks 30 minutes on flat ground most days. He has had no falls since starting physical therapy. His glucose sensor shows no low readings. He has had no abdominal swelling, black stools, confusion or yellowing of the eyes. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 57 |
| Liver | Hepatitis C cured; compensated cirrhosis; carvedilol; next surveillance ultrasound in February |
| Alcohol | None since the start of treatment |
| Mood | PHQ-2 0 |
Health risk assessment. Completed by the patient on the clinic's online form before the visit and reviewed with him by Dr. Rasmussen. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good; better than in years |
| Psychosocial | Busy with appearances and travel; good support from family and friends |
| Substance use | No alcohol since February; never smoked; no drug use |
| Physical activity | Pool exercise twice a week; walks 30 minutes most days; some golf |
| Nutrition | Three meals and a late-evening snack; protein at each meal; less salt |
| Sleep | Six to seven hours; wakes with hip pain once a night |
| Falls and home safety | No falls since physical therapy; grab bars and a shower chair; cane on long walks |
| Driving | Drives in daytime; always wears a seat belt |
| Activities of daily living | Independent in all |
| Smoke alarms and firearms | Smoke alarms tested; no firearms at home |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; no fever or weight loss |
| Eyes | Negative | No vision change; retinal examination in June normal |
| Ears, nose, mouth, and throat | Negative | No hearing change or nosebleeds |
| Cardiovascular | Negative | No chest pain, palpitations or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No abdominal swelling, black stools or vomiting blood |
| Genitourinary | Negative | No urinary hesitancy, frequency or blood in the urine |
| Musculoskeletal | Positive | Hip, knee and back pain, about 4 of 10 |
| Integumentary | Negative | No yellowing, itching or new skin lesions |
| Neurological | Negative | No confusion, sleep reversal or tremor |
| Endocrine | Negative | No low glucose readings |
| Psychiatric | Negative | Mood good; PHQ-2 0 |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet twice daily with breakfast and supper | Oral route | 2021-03-01 | active | S |
| Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back pain | One tablet three times a day | Oral route | 2024-06-01 to 2026-01-12 | completed | S |
| Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofen | One capsule daily before breakfast | Oral route | 2024-06-01 to 2026-01-12 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a day | Two tablets up to twice a day as needed; no more than 2 g a day | Oral route | 2026-01-12 | active | S |
| Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day | 4 g to each knee up to four times a day | Topical route | 2026-01-12 | active | S |
| Carvedilol 6.25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-26 to 2026-02-23 | completed | S |
| Carvedilol 12.5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-02-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-26 | active | S |
| Sofosbuvir 400 mg and velpatasvir 100 mg oral tablet, one tablet daily for 12 weeks | One tablet daily for 12 weeks | Oral route | 2026-02-23 to 2026-05-17 | completed | S |
| Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral capsule, one capsule daily | One capsule daily | Oral route | 2026-02-23 | active | S |
| Zoledronic acid 5 mg in 100 mL, intravenous infusion over at least 15 minutes, once a year | Once a year | Intravenous route | 2026-06-01 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-21 | Body height | 178 | cm | S |
| 2026-09-21 | Body weight | 82.4 | kg | S |
| 2026-09-21 | Body mass index (BMI) [Ratio] | 26 | kg/m2 | S |
| 2026-09-21 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-09-21 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-09-21 | Heart rate | 62 | /min | S |
| 2026-09-21 | Respiratory rate | 14 | /min | S |
| 2026-09-21 | Body temperature | 36.6 | Cel | S |
| 2026-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-21 | Cholesterol [Mass/volume] in Serum or Plasma | 148 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-09-21 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 68 | mg/dL | Goal below 100 mg/dL in diabetes, below 70 if higher risk | Normal | S |
| 2026-09-21 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 42 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-09-21 | Triglyceride [Mass/volume] in Serum or Plasma | 140 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-09-21 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 1.3 | ng/mL | <=4 ng/mL | Normal | S |
| 2026-09-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-09-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 82.4 kg; blood pressure 122/74; pulse 62 |
| Eyes | No scleral icterus |
| Skin | A few spider angiomas on the chest, fewer than before; palmar erythema; no jaundice |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear |
| Abdomen | Spleen tip palpable; no ascites or tenderness |
| Musculoskeletal | Reduced hip rotation on both sides; old fracture deformities of the forearms; knees with crepitus |
| Feet | Monofilament sensation intact; pulses present; no ulcers |
| Neurological | No asterixis; gait slow but steady; Timed Up and Go 11 seconds |
| Psychiatric | Cheerful and blunt |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1992 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review ordered | resolved | confirmed | R74.01 | S — Synthetic presenting problem; no symptom or result of his real illness was made public. Superseded at the hepatology consultation. |
| Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis C | resolved | confirmed | B18.2 | S — Synthetic genotype, viral load and timing; his hepatitis C and its likely transfusion source are documented (D). |
| Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleeding | active | confirmed | K74.69 | S — Synthetic stage of liver disease linked to his documented hepatitis C and later liver transplant. |
| Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII) | active | confirmed | K76.6 | S — Synthetic finding at the hepatology consultation. |
| Type 2 diabetes on metformin, A1c 7.4% | active | confirmed | E11.65 | S — Synthetic; diabetes is documented only in his last years (D), and placing it at 57 is a synthetic choice. |
| Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioids | active | confirmed | G89.29 | S — Synthetic pain at the index age, anchored to his documented fractures and the pain of his later years. |
| Osteoporosis in a man with cirrhosis, prior heavy alcohol use and dozens of old fractures: femoral neck T-score -2.6, lumbar spine -1.9 | active | confirmed | M81.8 | S — Synthetic bone density result. |
| Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) | resolved | confirmed | E55.9 | S — Synthetic finding before the bone density scan. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 122/74 mmHg on carvedilol |
| Depression screening | Completed today | PHQ-2 score 0; PHQ-9 3 a month ago |
| Unhealthy alcohol use screening and counseling | Completed today | No alcohol since February; abstinence reinforced |
| Tobacco use | Completed today | Never |
| Colorectal cancer screening | Ordered | Never screened; colonoscopy ordered |
| Prostate cancer screening | Completed today | Shared decision; he chose testing; PSA 1.3 ng/mL |
| Lung cancer screening | Not indicated | Never smoked |
| Diabetes and lipid care | Completed today | Glucose management indicator 6.8%; LDL 68 mg/dL on atorvastatin; urine albumin normal in January |
| Hepatitis C, hepatitis B and HIV screening | Up to date | Hepatitis C treated and cured; hepatitis B and HIV negative in January |
| Liver cancer surveillance | Up to date | Ultrasound and alpha-fetoprotein in August; next in February |
| Osteoporosis | Up to date | Zoledronic acid in June; bone density again in two years |
| Fall risk | Completed today | No falls since physical therapy; Timed Up and Go 11 seconds |
| Influenza, pneumococcal, zoster and Tdap vaccines | Completed today | Given today |
| Hepatitis A and B vaccines | Up to date | Both two-dose series complete |
| COVID-19 vaccine, this season | Due | At his pharmacy this autumn |
| Dental and eye examinations | Up to date | Dental review before zoledronic acid in May; retinal examination in June |
Immunizations given today: Influenza vaccine, inactivated, trivalent, preservative free, this season; Pneumococcal conjugate vaccine PCV20; Recombinant zoster vaccine, dose 1 of 2; Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) [S]
Guideline basis: Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023); American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); Adult Immunization Schedule by Medical Condition and Other Indication (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Colorectal Cancer: Screening (2021); Prostate Cancer: Screening (2018)
Follow-up: Colonoscopy in the next two months. Liver ultrasound with alpha-fetoprotein in February. Hepatology review with liver stiffness a year after cure. Second zoster dose in two to six months. Next preventive visit in one year. [S]
Voluntary advance care planning discussion of about 20 minutes, with his consent. He wants full treatment, including a liver transplant evaluation if his liver ever fails, and wants to be told plainly how he is doing. He named a health care agent, recorded in the confidential part of the chart and not named here. He chose not to complete other treatment preferences today. To be revisited yearly or if his health changes. [S]